Skip to main content
Normal View

Medicinal Products

Dáil Éireann Debate, Tuesday - 1 December 2020

Tuesday, 1 December 2020

Questions (694)

Matt Shanahan

Question:

694. Deputy Matt Shanahan asked the Minister for Health the downstream and overall cost-benefit analysis conducted by the corporate pharmaceutical unit when assessing reimbursement applications for novel and generic drug applications; his views on whether the full system savings are being considered in such applications; if evidence of same in action can be demonstrated; and if he will make a statement on the matter. [39906/20]

View answer

Written answers

The Health Service Executive has operational responsibility for medicines expenditure, thus the matter has been referred to the HSE for their attention and direct reply to the Deputy.

Top
Share